必威体育登录手机Agilent Technologies Inc.(NYSE: A) today announced the company has completed its acquisition of BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO) that specializes in biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.
All closing conditions are completed, including receipt of regulatory approvals.必威体育登录手机BIOVECTRA is now part of Agilent's Diagnostics and Genomics Group.
必威体育登录手机"We are delighted to officially welcome the BIOVECTRA team to Agilent," said Agilent President and CEO Padraig McDonnell."This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing."
必威体育登录手机With the addition of BIOVECTRA, Agilent will expand its portfolio of CDMO services, add rapidly growing modalities, and bring world-class capabilities to support gene editing.Additional details are available in thenews releaseannouncing the acquisition agreement.
必威体育登录手机Agilent expects the transaction will be $0.05 dilutive to non-GAAP earnings per share (EPS) in the first full year after closing and deliver a double-digit return on invested capital (ROIC) by year five.必威体育登录手机Agilent funded the transaction using a mix of cash on hand and debt financing.
Additional Information:
FAQs for customers
Highlights for Investors
必威体育登录手机About Agilent's Oligonucleotide GMP Manufacturing
About BIOVECTRA